MA43518B1 - 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase - Google Patents

3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase

Info

Publication number
MA43518B1
MA43518B1 MA43518A MA43518A MA43518B1 MA 43518 B1 MA43518 B1 MA 43518B1 MA 43518 A MA43518 A MA 43518A MA 43518 A MA43518 A MA 43518A MA 43518 B1 MA43518 B1 MA 43518B1
Authority
MA
Morocco
Prior art keywords
azabicyclo
hexanes
serving
substituted
ketohexokinase
Prior art date
Application number
MA43518A
Other languages
English (en)
Other versions
MA43518A (fr
Inventor
Aaron Smith
Kentaro Futatsugi
Kim Huard
Matthew Dowling
Dilinie Fernando
Thomas Victor Magee
Brian Raymer
Andre Shavnya
Benjamin Thuma
Andy Tsai
Meihua Tu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA43518A publication Critical patent/MA43518A/fr
Publication of MA43518B1 publication Critical patent/MA43518B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

L'invention concerne des 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase, des procédés de fabrication de ces composés ainsi que des procédés comprenant l'administration desdits composés à un mammifère en ayant besoin.
MA43518A 2015-12-29 2016-12-16 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase MA43518B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562272598P 2015-12-29 2015-12-29
US201662423549P 2016-11-17 2016-11-17
PCT/IB2016/057728 WO2017115205A1 (fr) 2015-12-29 2016-12-16 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase

Publications (2)

Publication Number Publication Date
MA43518A MA43518A (fr) 2018-11-07
MA43518B1 true MA43518B1 (fr) 2021-05-31

Family

ID=57755415

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43518A MA43518B1 (fr) 2015-12-29 2016-12-16 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase

Country Status (39)

Country Link
US (6) US9809579B2 (fr)
EP (1) EP3397631B1 (fr)
JP (1) JP6503515B2 (fr)
KR (1) KR102073048B1 (fr)
CN (1) CN108473469B (fr)
AU (1) AU2016380920B2 (fr)
CA (1) CA2952466A1 (fr)
CL (1) CL2018001667A1 (fr)
CO (1) CO2018006714A2 (fr)
CU (1) CU24540B1 (fr)
CY (1) CY1124389T1 (fr)
DK (1) DK3397631T3 (fr)
EC (1) ECSP18048517A (fr)
ES (1) ES2871251T3 (fr)
GE (1) GEP20207147B (fr)
HK (1) HK1259073A1 (fr)
HR (1) HRP20210769T1 (fr)
HU (1) HUE054380T2 (fr)
IL (1) IL260330B (fr)
LT (1) LT3397631T (fr)
MA (1) MA43518B1 (fr)
MD (1) MD3397631T2 (fr)
MX (1) MX2018007755A (fr)
NI (1) NI201800072A (fr)
PE (1) PE20181289A1 (fr)
PH (1) PH12018501375A1 (fr)
PL (1) PL3397631T3 (fr)
PT (1) PT3397631T (fr)
RS (1) RS61896B1 (fr)
RU (1) RU2696269C1 (fr)
SG (1) SG11201804363UA (fr)
SI (1) SI3397631T1 (fr)
SV (1) SV2018005709A (fr)
TN (1) TN2018000198A1 (fr)
TW (1) TWI653232B (fr)
UA (1) UA121271C2 (fr)
UY (1) UY37051A (fr)
WO (1) WO2017115205A1 (fr)
ZA (1) ZA201803449B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2018000198A1 (en) * 2015-12-29 2019-10-04 Pfizer Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
SG11201901729YA (en) 2016-09-02 2019-03-28 Ironwood Pharmaceuticals Inc Fused bicyclic sgc stimulators
CN109316601B (zh) * 2017-07-31 2021-11-09 武汉朗来科技发展有限公司 药物组合物及其用途
US10934279B2 (en) 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
MX2021002428A (es) * 2018-08-31 2023-01-02 Pfizer Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas.
TWI714231B (zh) * 2018-09-04 2020-12-21 美商美國禮來大藥廠 2,6-二胺基吡啶化合物
KR102558308B1 (ko) * 2018-09-27 2023-07-24 주식회사 엘지화학 3-아자바이사이클로[3,1,1]헵탄 유도체 및 이를 포함하는 약제학적 조성물
CA3127130A1 (fr) * 2019-01-29 2020-08-06 Shandong Xuanzhu Pharma Co., Ltd. Inhibiteur de glycokinase hexanone et son utilisation
CA3140972A1 (fr) 2019-05-20 2020-11-26 Pfizer Inc. Combinaisons comprenant du benzodioxol en tant qu'agonistes de glp-1r destinees a etre utilisees dans le traitement de la nash/nafld et de maladies associees
CN111978296A (zh) * 2019-05-22 2020-11-24 山东轩竹医药科技有限公司 己酮糖激酶抑制剂及其用途
JP2022534425A (ja) 2019-05-31 2022-07-29 イケナ オンコロジー， インコーポレイテッド Ｔｅａｄ阻害剤およびその使用
TWI750685B (zh) * 2019-06-17 2021-12-21 美商美國禮來大藥廠 二取代吡唑化合物
CA3163979A1 (fr) 2019-12-10 2021-06-17 Pfizer Inc. Formes solides de 2-((4-((s)-2-(5-chloropyridine-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidine-1-yle)methyle)-1-(((s)-oxetan-2-yl)methyle) -1h-benzo[d] imidazole-6-acide carb oxylique, 1,3-dihydroxy-2-(hydroxymethyle)propane-2-sel d'amine
KR20220127839A (ko) * 2019-12-24 2022-09-20 항저우 종메이화동 파마슈티칼 컴퍼니 리미티드 Khk 억제 효과를 갖는 화합물
CN114846008A (zh) * 2019-12-25 2022-08-02 杭州中美华东制药有限公司 具有果糖激酶(khk)抑制作用的嘧啶类化合物
GB202001856D0 (en) * 2020-02-11 2020-03-25 Inorbit Therapeutics Ab Compounds useful in inhibiting ketohexokinase and methods of making and using the same
US20230167087A1 (en) 2020-02-13 2023-06-01 Eli Lilly And Company 2-[2-methylazetidin-1-yl]-4-phenyl-6-(trifluoromethyl)-pyrimidine compounds
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
IL296694A (en) 2020-03-27 2022-11-01 Pfizer Treatment of type 2 diabetes, obesity or excess weight using 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[( 2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or its pharmaceutical salts
JP2023522725A (ja) * 2020-04-20 2023-05-31 エルジー・ケム・リミテッド ３－アザビシクロアルキル誘導体およびこれを含む薬剤学的組成物
CN111423420A (zh) * 2020-04-30 2020-07-17 广州博济医药生物技术股份有限公司 作为己酮糖激酶抑制剂的并环化合物
CN113754640B (zh) * 2020-06-03 2023-02-14 山东轩竹医药科技有限公司 氘代的己酮糖激酶抑制剂及其用途
EP4190776A4 (fr) * 2020-07-28 2024-02-28 Shandong Xuanzhu Pharma Co Ltd Forme de sel et forme cristalline d'un inhibiteur de cétohexokinase et utilisation associée
CN116438200A (zh) 2020-09-10 2023-07-14 普雷西里克斯公司 针对fap的抗体片段
CN116635377A (zh) 2020-12-25 2023-08-22 四川海思科制药有限公司 己酮糖激酶抑制剂及其用途
US20230079863A1 (en) 2021-03-29 2023-03-16 Gilead Sciences, Inc. Khk inhibitors
KR20220136939A (ko) 2021-04-01 2022-10-11 주식회사 엘지화학 옥사디아졸 화합물 및 이를 포함하는 약제학적 조성물
WO2022262841A1 (fr) * 2021-06-17 2022-12-22 杭州中美华东制药有限公司 Forme de sel et forme cristalline de composé spiro et son procédé de préparation
AU2022336407A1 (en) 2021-08-31 2024-02-22 Pfizer Inc. Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
WO2023061492A1 (fr) * 2021-10-14 2023-04-20 华领医药技术（上海）有限公司 Dérivé de 2-oxo-3-azabicyclo[3.1.0]hexane
WO2023111817A1 (fr) 2021-12-17 2023-06-22 Pfizer Inc. Formes cristallines d'acide [(1r,5s,6r)-3-{2-[(2s)-2-méthylazetidin-1-yl]-6-(trifluorométhyl) pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acétique
TW202340174A (zh) * 2021-12-24 2023-10-16 南韓商Ｌｇ化學股份有限公司 （ｓ）－２－（２－甲基四氫吖唉－１－基）嘧啶衍生物及包含彼之醫藥組成物
CN114315494B (zh) * 2021-12-29 2023-09-22 苏州楚凯药业有限公司 一种(s)-2-甲基氮杂环丁烷盐酸盐的制备方法
WO2023151473A1 (fr) * 2022-02-09 2023-08-17 上海研健新药研发有限公司 Inhibiteur de khk, son procédé de préparation et son utilisation
WO2023203135A1 (fr) 2022-04-22 2023-10-26 Precirix N.V. Anticorps radiomarqué amélioré
WO2023213801A1 (fr) 2022-05-02 2023-11-09 Precirix N.V. Pré-ciblage
WO2023228023A1 (fr) 2022-05-23 2023-11-30 Pfizer Inc. Traitement du diabète de type 2 ou contrôle de la gestion du poids avec de l'acide 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-méthylbenzo[d][1,3]dioxol-4-yl)pipéridin-1-yl)méthyl)-1-(((s)-oxétan-2-yl)méthyl)-1h-benzo[d]imidazole-6-carboxylique ou un sel pharmaceutique de celui-ci

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980350A (en) 1988-02-25 1990-12-25 Merck & Co., Inc. Piperazinylalkylpyrimidines as hypoglycemic agents
DE4208254A1 (de) 1992-03-14 1993-09-16 Hoechst Ag Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
PL203771B1 (pl) 1998-07-06 2009-11-30 Bristol Myers Squibb Co Pochodna bifenylosulfonamidu jako dualny antagonista receptorów angiotensyny i endoteliny, sposób jej wytwarzania i jej zastosowanie oraz pochodna bifenylu i pochodna benzenu
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
DE60219295T2 (de) 2001-02-28 2008-01-03 Merck & Co., Inc. Acylierte piperidinderivate als melanocortin-4-rezeptoragonisten
KR20040095239A (ko) 2002-02-27 2004-11-12 화이자 프로덕츠 인코포레이티드 Ａｃｃ 억제제
GEP20084421B (en) 2004-05-12 2008-07-10 Pfizer Prod Inc Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
CA2568056A1 (fr) 2004-05-25 2005-12-08 Pfizer Products Inc. Derives de tetraazabenzo[e]azulene et analogues de ceux-ci
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
ES2487967T3 (es) 2006-04-20 2014-08-25 Pfizer Products Inc. Compuestos amido heterocíclicos condensados con fenilo para la prevención y el tratamiento de enfermedades mediadas por la glucoquinasa
US8933201B2 (en) 2006-06-07 2015-01-13 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
WO2008024902A2 (fr) 2006-08-23 2008-02-28 University Of Florida Research Foundation, Inc. Ciblage de fructokinase comme thérapie pour une maladie cardiovasculaire, un syndrome métabolique et une affection rénale
CN101541809A (zh) 2006-11-29 2009-09-23 辉瑞产品公司 螺环酮乙酰基-CoA羧化酶抑制剂
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
JP5411867B2 (ja) * 2007-10-11 2014-02-12 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規ｓＥＨ阻害剤およびそれらの使用
US20110009443A1 (en) 2008-05-28 2011-01-13 Kevin Daniel Freeman-Cook Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors
EP2297163B1 (fr) 2008-05-28 2015-07-08 Pfizer Inc. Inhibiteurs de la pyrazolospirocétone acétyl-CoA carboxylase
JP2011529483A (ja) 2008-07-29 2011-12-08 ファイザー・インク フッ素化ヘテロアリール
WO2010013222A1 (fr) * 2008-07-30 2010-02-04 Ranbaxy Laboratories Limited Dérivés d'acide pyrrole carboxylique en tant qu'agents antibactériens
BRPI0918841B8 (pt) 2008-08-28 2021-05-25 Pfizer derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos
WO2010086820A1 (fr) 2009-02-02 2010-08-05 Pfizer Inc. Dérivés de 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazépin-6(5h)-yl)phényle
WO2010103438A1 (fr) 2009-03-11 2010-09-16 Pfizer Inc. Indazole amides substitués
EP2406253B1 (fr) 2009-03-11 2013-07-03 Pfizer Inc. Dérivés de benzofuranyle utilisés comme inhibiteurs de la glucokinase
EP2408780A2 (fr) 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicycloý3,3.1¨nonanes
US8288385B2 (en) 2009-04-08 2012-10-16 Actelion Pharmaceuticals Ltd. 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines
CA2759843A1 (fr) 2009-05-08 2010-11-10 Pfizer Inc. Modulateurs de gpr119
EP2427448A1 (fr) 2009-05-08 2012-03-14 Pfizer Inc. Modulateurs du gpr119
NZ596467A (en) 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (fr) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Agonistes du récepteur de la neuromédine u et leurs utilisations
KR101686913B1 (ko) 2009-08-13 2016-12-16 삼성전자주식회사 전자기기에서 이벤트 서비스 제공 방법 및 장치
ES2545811T3 (es) 2010-04-22 2015-09-16 Janssen Pharmaceutica Nv Compuestos de indazol útiles como inhibidores de quetohexoquinasa
US9387245B2 (en) 2010-08-06 2016-07-12 University Of Colorado, A Body Corporate Methods and compositions for the inhibition of fructokinase
CN102432598A (zh) * 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 三环化合物、其制备方法及其在医药上的应用
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
EA201691587A1 (ru) 2014-02-11 2017-01-30 Элнилэм Фармасьютикалз, Инк. КОМПОЗИЦИИ НА ОСНОВЕ iRNA ДЛЯ КЕТОГЕКСОКИНАЗЫ (KHK) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
TN2018000198A1 (en) * 2015-12-29 2019-10-04 Pfizer Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors

Also Published As

Publication number Publication date
PT3397631T (pt) 2021-05-28
US20200148669A1 (en) 2020-05-14
US10787438B2 (en) 2020-09-29
TN2018000198A1 (en) 2019-10-04
SG11201804363UA (en) 2018-07-30
US20210309644A1 (en) 2021-10-07
HRP20210769T1 (hr) 2021-06-25
KR102073048B1 (ko) 2020-02-04
CU24540B1 (es) 2021-08-06
DK3397631T3 (da) 2021-05-25
CO2018006714A2 (es) 2018-07-10
PL3397631T3 (pl) 2021-09-20
UY37051A (es) 2017-07-31
US9809579B2 (en) 2017-11-07
CL2018001667A1 (es) 2018-08-03
US20180037575A1 (en) 2018-02-08
GEP20207147B (en) 2020-09-10
PE20181289A1 (es) 2018-08-07
ECSP18048517A (es) 2018-07-31
NI201800072A (es) 2018-11-22
UA121271C2 (uk) 2020-04-27
EP3397631A1 (fr) 2018-11-07
RS61896B1 (sr) 2021-06-30
TWI653232B (zh) 2019-03-11
US10988463B2 (en) 2021-04-27
IL260330B (en) 2021-07-29
US20190106412A1 (en) 2019-04-11
PH12018501375A1 (en) 2019-02-11
CN108473469B (zh) 2020-11-03
CY1124389T1 (el) 2022-07-22
US11634410B2 (en) 2023-04-25
BR112018012047A2 (pt) 2018-12-04
EP3397631B1 (fr) 2021-04-07
MX2018007755A (es) 2018-11-09
SV2018005709A (es) 2018-09-10
CN108473469A (zh) 2018-08-31
LT3397631T (lt) 2021-06-10
JP2019500383A (ja) 2019-01-10
RU2696269C1 (ru) 2019-08-01
MA43518A (fr) 2018-11-07
CA2952466A1 (fr) 2017-06-29
KR20180083427A (ko) 2018-07-20
JP6503515B2 (ja) 2019-04-17
TW201726659A (zh) 2017-08-01
US10174007B2 (en) 2019-01-08
ES2871251T3 (es) 2021-10-28
AU2016380920B2 (en) 2019-10-31
AU2016380920A1 (en) 2018-06-14
ZA201803449B (en) 2019-02-27
US20170183328A1 (en) 2017-06-29
MD3397631T2 (ro) 2021-08-31
WO2017115205A1 (fr) 2017-07-06
HK1259073A1 (zh) 2019-11-22
IL260330A (en) 2018-08-30
SI3397631T1 (sl) 2022-01-31
US20200377482A1 (en) 2020-12-03
HUE054380T2 (hu) 2021-09-28
CU20180046A7 (es) 2018-09-05

Similar Documents

Publication Publication Date Title
MA43518A (fr) 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
CL2018002291A1 (es) Anticuerpos anti-fgfr2iiib afucosilados (divisional solicitud 201600221)
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
MA38959A1 (fr) Modulateurs du facteur b du complément
UY36275A (es) Compuestos aminopirimidinilo
WO2015168635A3 (fr) Compositions et procédés pour moduler l'expression du facteur b du complément
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
WO2016057683A3 (fr) Nouveaux anticorps anti-nodaux et méthodes d'utilisation de ceux-ci
CL2021001643A1 (es) Moduladores de la expresión de hsd17b13
MA38816A (fr) Sulfamidase modifiée et sa production
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
EA201990198A1 (ru) Радиолиганды для визуализации фермента ido1
EA201890186A1 (ru) Применение штаммов микробактерий для получения антибактериальных агентов
BR112017002675A2 (pt) métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila
EA201892235A1 (ru) Гранулированная композиция для перорального применения
EA201991863A1 (ru) Составы амфетамина, препятствующие злоупотреблению
WO2015109318A3 (fr) Méthodes thérapeutiques
MA39877A (fr) Formes solides d'un composé pharmaceutiquement actif
MX2020003554A (es) Moduladores de la expresion de enac.
RU2016108801A (ru) Пептид, обладающий лечебным действием против болезни Альцгеймера
FR3049582B1 (fr) Turbomachine, telle par exemple qu'un turboreacteur ou un turbopropulseur